Newly emerging data suggest the Pfizer-BioNTech Covid vaccine works substantially less well at preventing infection and hospitalizations in children aged 5 to 11 than it does in those aged 12 to 17 — a finding that is raising questions about whether the companies chose the wrong dose for the younger children.
Extended dosing intervals for Pfizer or Moderna vaccines may be considered for certain individuals ages 12 to 64 years, not only to lower the risk of vaccine-associated myocarditis, but to potentially improve vaccine effectiveness, CDC staff said on Thursday.
According to the agency's new interim guidance, young people ages 12 to 39 may especially benefit from a second mRNA dose 8 weeks after their first dose.
The island has maintained some of the lowest case rates in the world throughout the pandemic - lasting more than 200 days in 2020 without a single case.
At this point, one thing about the pandemic is clear: The COVID-19 vaccines, even when followed by a booster, aren't going to stop the coronavirus — or provide long-term protection from infections.
Recent Comments